# EDGAR Filing Document

**Accession Number:** 0000842023
**File Stem:** 0001062993-25-013359
**Filing Date:** 2025-7
**Character Count:** 9170
**Document Hash:** 39c7d7471baeb6ff708576696206c976
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-25-013359.hdr.sgml**: 20250731

**ACCESSION NUMBER**: 0001062993-25-013359

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250729

**FILED AS OF DATE**: 20250731

**DATE AS OF CHANGE**: 20250731

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Hippel James
- **CENTRAL INDEX KEY:** 0001603594

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17272
- **FILM NUMBER:** 251172055

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-TECHNE Corp
- **CENTRAL INDEX KEY:** 0000842023
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411427402
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 614 MCKINLEY PL N E
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
- **BUSINESS PHONE:** 6123798854

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TECHNE CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Hippel James<br><sub>(Last) (First) (Middle)</sub><br>614 MCKINLEY PLACE NE<br><sub>(Street)</sub><br>MINNEAPOLIS, MN 55413<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-29 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CFO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BIO-TECHNE Corp [ TECH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-07-29 |  | M |  | 168620 | A | $44.33 | 275230 | D |  |
| Common Stock | 2025-07-29 |  | F |  | 147431 | D | $58.55 | 127799 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to Buy) | $44.33 | 2025-07-29 |  | M |  |  | 168620 | <sup>(1)</sup> | 2025-08-08 | Common Stock | 168620 | $0 | 0 | D |  |
| Stock Options (Right to Buy) | $47.60 |  |  |  |  |  |  | <sup>(1)</sup> | 2026-08-07 | Common Stock | 186068 |  | 186068 | D |  |
| Stock Options (Right to Buy) | $66.97 |  |  |  |  |  |  | <sup>(1)</sup> | 2027-08-05 | Common Stock | 167328 |  | 167328 | D |  |
| Stock Options (Right to Buy) | $120.46 |  |  |  |  |  |  | <sup>(2)</sup> | 2028-08-06 | Common Stock | 40536 |  | 40536 | D |  |
| Performance Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 10912 |  | 10912 | D |  |
| Performance Stock Options (Right to Buy) | $94.52 |  |  |  |  |  |  | <sup>(4)</sup> | 2029-08-15 | Common Stock | 33916 |  | 33916 | D |  |
| Stock Options (Right to Buy) | $94.52 |  |  |  |  |  |  | <sup>(5)</sup> | 2029-08-15 | Common Stock | 45220 |  | 45220 | D |  |
| Performance Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 13865 |  | 13865 | D |  |
| Performance Stock Options (Right to Buy) | $84.61 |  |  |  |  |  |  | <sup>(6)</sup> | 2030-08-15 | Common Stock | 37314 |  | 37314 | D |  |
| Stock Options (Right to Buy) | $84.61 |  |  |  |  |  |  | <sup>(7)</sup> | 2030-08-15 | Common Stock | 45923 |  | 45923 | D |  |
| Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 13159 |  | 13159 | D |  |
| Performance Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(9)</sup> | <sup>(9)</sup> | Common Stock | 24062 |  | 24062 | D |  |
| Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 12031 |  | 12031 | D |  |
| Stock Options (Right to Buy) | $74.91 |  |  |  |  |  |  | <sup>(11)</sup> | 2034-08-15 | Common Stock | 32417 |  | 32417 | D |  |
| Restricted Stock Units | <sup>(3)</sup> |  |  |  |  |  |  | <sup>(12)</sup> | <sup>(12)</sup> | Common Stock | 34634 |  | 34634 | D |  |

---

### Footnotes:

(1) Fully exercisable.

(2) Options to purchase 10,134 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.

(3) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

(4) Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(5) Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

(6) Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(7) Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.

(8) 13,159 restricted stock units vest on 11/1/2025.

(9) Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

(10) 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027.

(11) Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.

(12) 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.

**Signature:** /s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed  
**Date:** 2025-07-31

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**